Data show that some people with early-stage non-small cell lung cancer can benefit significantly from treatment with a targeted therapy, and COVID-19 slows the rate of enrollment in cancer clinical trials.

by Kate Yandell

A study shows that a more tolerable, dose-adjusted chemotherapy regimen can effectively treat a rare lymphoma, and data from registries provide information on which cancer patients are at greatest risk of death from COVID-19.

by Kate Yandell

A study finds that metastatic prostate cancer incidence rose after the U.S. Preventive Services Task Force urged against routine PSA testing, and the Food and Drug Administration approves two PARP inhibitors for treatment of prostate cancer.

by Kate Yandell

A study indicates that children with cancer are not at increased risks of severe cases of COVID-19, and researchers find that Medicaid expansion was associated with reduced cancer deaths.

by Kate Yandell

A study finds that opioid deaths have slightly increased among people with cancer, and the Food and Drug Administration approves a targeted therapy for non-small cell lung cancer.

by Kate Yandell

At the AACR Virtual Annual Meeting I, researchers presented new data on cancer biology, treatment, screening and risk reduction.

by Cancer Today Staff

A third of cancer survivors report that they or their partners have stayed in jobs due to concerns about keeping health insurance, and the Food and Drug Administration approves a new treatment for metastatic triple-negative breast cancer.

by Kate Yandell

A study shows that antibiotic use prior to starting immunotherapy for melanoma is associated with decreased survival, and the Food and Drug Administration approves a treatment for advanced HER2-positive breast cancer.

by Kate Yandell

A study indicates that the rate of e-cigarette use is elevated in young adults with a history of cancer, and oncologists write about the impact of COVID-19.

by Kate Yandell

CAR-T cell therapy shows promise for treating mantle cell lymphoma, and the Food and Drug Administration requests that drugmakers pull the anti-heartburn drug ranitidine due to concerns about a contaminant that may increase cancer risk.

by Kate Yandell